[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hydroxychloroquine-retinopathy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hydroxychloroquine-retinopathy":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,69],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100466567","adaptive-optics-imaging-of-outer-retinal-diseases-100466567",false,"NCT05355415","Adaptive Optics Imaging of Outer Retinal Diseases","Inclusion Criteria:\n\n1. Are 21 years of age or older,\n2. Have the ability to cooperate with instructions during adaptive optics imaging (similar to instructions given during a clinical eye exam),\n3. Have the ability to understand and sign an informed consent. (Non-English speaking participants will not be enrolled into the study), and\n4. Have been diagnosed with outer retinal disease or condition (Cohort 2).\n\nExclusion Criteria:\n\n1. Have a condition which prevents adequate images from being obtained (e.g. unstable fixation or media opacity),\n2. Have visual correction outside of the range +4 diopters (D) to -8 D,\n3. Have a history of adverse reaction to mydriatic drops,\n4. Have a predisposition to (i.e., narrow iridocorneal angle) or any history of acute angle closure glaucoma (AACG), or\n5. Are working under the direct supervision of Drs. Hammer, Cukras and Liu, or any of the NIH\u002FNEI AIs.","ALL","21 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","The objective of the study is to collect adaptive optics (AO) retinal images from human subjects with outer retinal diseases (diseases of the outer retina including photoreceptor, retinal pigment epithelium (RPE), basement membrane or choroidal pathologies) to develop new diagnostic methods, biomarkers, and clinical endpoints.",[23,24,25,26,27,28,29,30,31,32],"Retinal Degeneration","Age-Related Macular Degeneration","Retinitis Pigmentosa","Hydroxychloroquine Retinopathy","Usher Syndromes","Late-Onset Retinal Degeneration","Cone Dystrophy","Cone Rod Dystrophy","Rod Cone Dystrophy","Rod Dystrophy","RECRUITING","2026-05-06",{"date":36,"type":37},"2026-05-08","ACTUAL",{"date":39,"type":37},"2021-08-27",{"date":41,"type":19},"2028-09-30",{"name":43,"class":44},"Food and Drug Administration (FDA)","FED",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100624446","optical-coherence-tomography-angiography-evaluation-of-patients-taking-hydroxychloroquine-100624446","NCT07409740","Optical Coherence Tomography Angiography Evaluation Of Patients Taking Hydroxychloroquine","Inclusion Criteria:\n\n* Adults (≥18 years old) with documented HCQ therapy for ≥1 year.\n* Stable systemic disease under medical supervision.\n\nExclusion Criteria:\n\n* -patients with media opacity.\n* Any pre-existing retinal or optic nerve disease (e.g., diabetic retinopathy, AMD, myopic degeneration).\n* History of intraocular surgery or trauma.\n* Uncontrolled systemic vascular diseases (e.g., hypertension)",true,"18 Years",{"count":55,"type":19},90,"This study aims to evaluate retinal and choroidal microvascular changes using optical coherence tomography angiography (OCTA) in patients receiving hydroxychloroquine therapy. Hydroxychloroquine is commonly used in the treatment of autoimmune diseases and may cause retinal toxicity with long-term use. OCTA is a non-invasive imaging modality that allows detailed assessment of retinal vascular changes.",[26],"NOT_YET_RECRUITING","2026-02-08",{"date":61,"type":37},"2026-02-13",{"date":63,"type":19},"2026-02-01",{"date":65,"type":19},"2026-09-01",{"name":67,"class":68},"Sohag University","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":53,"maxAge":4,"enrollmentInfo":76,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":78,"conditions":79,"keywords":80,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100518849","novel-erg-for-detection-of-hydroxychloroquine-retinopathy-100518849","NCT06035887","Novel ERG for Detection of Hydroxychloroquine Retinopathy","A Feasibility Study Using Novel, Portable Electroretinography Devices to Detect Hydroxychloroquine Retinopathy","Inclusion Criteria:\n\n1. Age ≥18 years\n2. HCQ groups:\n\n   a. HCQ use \\>5 years for patients without any high-risk factors, or \\>1 year in patients with one or more high-risk factors for HCQ retinopathy, namely: i. Dose \\>5mg\u002Fkg per day actual body weight (ABW) ii. Estimated glomerular filtration rate (eGFR) of \\\u003C60mls\u002Fmin\u002F1.73m2 iii. Concomitant tamoxifen use\n3. Control group:\n\n   1. No prior HCQ exposure\n\nExclusion Criteria:\n\n1. Cataract grade ≥3 of any subtype\n2. Recent cataract surgery within 4 weeks of recruitment\n3. Significant media opacity or corneal disease including, but not limited to, corneal oedema, corneal scarring, keratoconus, previous corneal transplants, severe keratoconjunctivitis sicca (requiring the use of topical serum, immunosuppressive or analogous therapy, or procedural treatment).\n4. Significant macular co-pathology including, but not limited to, macular degeneration, macular scarring, cystic macular oedema (for any reason), staphyloma.\n5. Inherited retinal and\u002For macular dystrophies including colour vision deficiencies\n6. Active or previous posterior uveitis or pan-uveitis\n7. Aphakia\n8. High refractive error \\>6.00 dioptres\n9. Amblyopia\n10. Diabetes\n11. Retinal angiopathies including, but no limited to, retinal vein occlusion, retinal artery occlusion, ocular ischaemic syndrome, HIV retinopathy, Sickle cell disease, radiation retinopathy\n12. Visually significant surgical retinal disease including epiretinal membrane, macular hole, retinal detachment, retinal tear\n13. Previous retinal laser or intravitreal treatment\n14. Moderate or worse glaucoma\n15. Optic atrophy\n16. Photosensitive epilepsy\n17. Ungradable HCQ retinopathy screening images\n18. Periocular infection or rash (recruitment can be deferred until acute pathology has resolved)\n19. Unable or unwilling to undertake study activities\n20. Any active use or history of the following medications:\n\nAmiodarone Canthaxanthin Deferoxamine Digoxin Ethambutol Interferon-alpha Melatonin Nefazodone Sildenafil Vigabatrin Chloroquine Quinine",{"count":77,"type":19},140,"The purpose of the study is to investigate novel electroretinography (ERG) devices in the detection of hydroxychloroquine retinopathy. Two devices (the RETEval full-field and flicker ERG and UTAS multifocal ERG) will be evaluated in this study, comparing device outputs to standard of care screening tests, in groups of participants characterised by presence or absence of hydroxychloroquine-related retinopathy.",[26],[81,82],"Electroretinography","Diagnostic Evaluation","2025-08-01",{"date":85,"type":37},"2025-08-06",{"date":87,"type":37},"2024-05-31",{"date":89,"type":19},"2026-05",{"name":91,"class":68},"King's College Hospital NHS Trust",1]